Drug Trial Radar · NCT00510783
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
Last checked: Nov 20, 2026Latest source record: Dec 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Jul 2007
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UCB Pharma
- First posted
- Aug 2, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a history of seizures can be involved. The patient must present to the emergency department within 4 hours of a seizure. The purpose of this study is to compare these three drugs, phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs can prevent another seizure in the next 24 hours. We are also looking for any possible side effects.
Conditions
- Tonic-clonic Seizure
Interventions
KeppraDrug
The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
FosphenytoinDrug
IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
DilantinDrug
IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Recurrent Seizure After Treatment.Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Grady Memorial Hospital
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.